Your Cholesterol Is Not a TikTok. Here’s What the Evidence Actually Says About Blood Testing.
He walked into Bay Four holding a piece of paper.
Not a phone. Actual paper. Printed. Eight pages, front and back, covered in numbers, abbreviations, and colour-coded flags. Green for good, yellow for borderline, red for out of range. He was 43, lean and athletic — CrossFit five times a week. He’d come in for chest pain.
The workup was clean. Normal ECG, clear chest X-ray, negative troponin. His chest pain turned out to be chemical gastritis — he’d been taking 800mg of ibuprofen three times a day for a week to manage a sore ankle. An easy fix.
But the paper changed the conversation.
It was a comprehensive fractionated lipid panel — one of those hundred-plus-test “longevity subscriptions” you can now buy online without a doctor. His HDL was excellent. Triglycerides, nice and low. But his LDL was 170 mg/dL. Meaningfully high.
Before I could raise it, he did.
“I know what you’re going to say about the LDL,” he told me. “But look at my HDL-to-triglyceride ratio. And the fractionation — it’s mostly large, fluffy particles. Those are the harmless kind.”
Here was a man who had done research, spent money, and tracked his biomarkers with genuine dedication. And through a steady diet of social media content from people selling a particular story, he had arrived at a conclusion that gave him permission to ignore a number that deserved his attention.
I wasn’t going to change his mind in that ED bay. But that conversation stayed with me. And it’s why this episode of Overheard in the Emergency Room exists.
Why Testing Needs a Clinical Question
There is a version of blood testing that is genuinely useful — and a version that is, at best, expensive noise and, at worst, a gateway to unnecessary supplements and anxiety.
The difference is not in the number of tests ordered. It is in whether the testing is answering a specific clinical question for a specific person, with a pathway to act on the result.
This is the logic embedded in how prevention guidelines are developed. The US Preventive Services Task Force — the USPSTF — is an independent expert panel whose sole job is to systematically review the evidence and make recommendations about preventive services for people without symptoms. Their process is rigorous: public nominations, independent evidence reviews, public comment periods, letter-graded recommendations.
Grade A and B recommendations are those where the evidence strongly supports routine screening. These are also the services that US insurers are required to cover at no cost. They represent the best answer to the question: “For this person, at this life stage, does this test change what we do next?”
That question — does this test change what we do next? — is the right question to ask of every blood test you’re considering.
What the New Cholesterol Guideline Actually Says
In March 2026, the American College of Cardiology and the American Heart Association, along with nine other medical societies, released a comprehensive new guideline on dyslipidemia management — the first major update since 2018. It matters, and it directly contradicts what my patient in Bay Four had been told.
A few headline changes worth knowing:
• LDL targets are back. The 2013 guidelines controversially removed specific cholesterol targets. The 2026 guideline restores them. For people without cardiovascular disease and no major risk factors, the LDL goal is below 100 mg/dL. With risk factors or diabetes, the target drops to below 70. For those who’ve already had a heart attack or stroke, the goal is below 55.
• Lp(a) should be checked once in every adult’s lifetime. Lipoprotein(a) is a genetically determined, largely lifestyle-resistant cardiovascular risk factor that standard panels miss entirely. Once tested, you never need to repeat it — it stays essentially constant. Know your number.
• ApoB has a clearer role. Apolipoprotein B measures the total number of atherogenic lipoprotein particles in your bloodstream — every LDL particle, large or small, carries exactly one ApoB molecule. In people with elevated triglycerides or diabetes, ApoB can reveal cardiovascular risk that LDL alone understates. It is not, however, a reason to replace a standard lipid panel with a boutique subscription panel.
• Earlier intervention matters. The guideline now recommends considering lipid-lowering therapy earlier — starting at age 30 in adults at high long-term risk. Exposure to elevated LDL is cumulative. Waiting until 55 to treat an LDL that’s been elevated since someone’s thirties is waiting too long.
The Large Fluffy LDL Myth
Let’s go directly to what my patient believed, because it is spreading rapidly in online health circles and it is causing harm.
The claim: small, dense LDL is the dangerous kind. Large, fluffy LDL is essentially harmless. Therefore, if your fractionated panel shows mostly large particles, a high LDL is nothing to worry about.
Here is what the science actually says. Small, dense LDL is particularly atherogenic — it penetrates arterial walls more easily, oxidises more readily, and has a longer circulation time. That part is true.
Large, fluffy LDL is not benign. Prospective studies consistently show that large buoyant LDL is independently associated with increased coronary heart disease risk. The risk is somewhat lower than with small dense particles — but it is not zero. And an LDL of 170 in any fractionation pattern is not fine.
The more clinically useful question is not what size your LDL particles are. It’s how many atherogenic particles — of any size — are circulating in your bloodstream. That’s what ApoB measures. Every LDL particle carries one ApoB molecule. Every one of them can enter an arterial wall. Every one of them contributes to the plaque that causes heart attacks and strokes.
When someone tells you your high LDL is fine because it’s the “good kind,” ask yourself who benefits from you believing that. In most cases, it is someone who wants you to continue eating a diet high in saturated fat without feeling concerned about your cardiovascular risk. That is motivated reasoning wearing a lab coat.
What to Ask Your GP
Here is a practical guide to the blood tests that actually matter in primary prevention, and how they connect to the Tier 1 lifestyle habits we cover throughout this series.
• CBC (Complete Blood Count): Flags anaemia, infection, immune issues. Diet — specifically adequate iron, B12, and folate — directly supports healthy red cell production.
• CMP (Comprehensive Metabolic Panel): Kidney function, liver function, glucose, electrolytes. Exercise improves insulin sensitivity and reduces fasting glucose. Alcohol and calorie excess affect liver markers.
• HbA1c and fasting glucose: Your glucose metabolism at a glance. If you’re in the prediabetes range (HbA1c 5.7–6.4%), intensive lifestyle intervention — diet, exercise, weight management — reduces progression to type 2 diabetes by approximately 50%.
• Lipid panel (Total cholesterol, LDL, HDL, triglycerides): Your core cardiovascular risk markers. A plant-rich diet lowers LDL. Exercise raises HDL and lowers triglycerides. Weight management improves all four. For those who need additional support, statins are the most evidence-supported intervention in preventive cardiology.
• ApoB and Lp(a): Increasingly recommended by guidelines. ApoB for those with elevated triglycerides or diabetes; Lp(a) once in a lifetime for everyone.
• TSH and thyroid function: Routinely recommended for women over 50. Hypothyroidism raises LDL and is easily treated.
• Vitamin D, B12, iron studies: Real conditions, genuinely common in certain populations. They do not require a subscription service to diagnose or treat.
The common thread in all of the above: each test is answering a specific question, for a person with a specific clinical context, in the hands of someone who can act on the result.
How Should This Modify Your Practice?
• If you have a GP: Call them this week. Book a preventive check. Ask what you’re due for based on your age and risk factors. This is the ounce of prevention.
• If you’ve had recent bloodwork: Pull out your results. If anything came back abnormal and wasn’t followed up, book an appointment to discuss it specifically.
• If a company is advertising a lab panel and selling you supplements: Ask whether they can prescribe medication if something is seriously wrong. Ask who reviews the results. Ask why they need to run 100 tests to answer the specific clinical question relevant to you. The answers will tell you a great deal.
• Regarding LDL: If your LDL is elevated, particle size does not give you a free pass. Ask your GP to calculate your 10-year and 30-year cardiovascular risk using the PREVENT equations and discuss targets together.
Extend Yourself
This episode of Overheard in the Emergency Room goes deeper — including a full walkthrough of the USPSTF and ADA prevention frameworks, a detailed breakdown of the 2026 AHA/ACC dyslipidemia guideline, and evidence-based mythbusting on the large-fluffy-LDL claim and supplement-linked lab panels.
You can listen on Spotify, watch on YouTube, and find the full episode notes and references at drcois.com.
Dr Cois
Emergency Physician. Creator of Overheard in the Emergency Room. Founder of DrCois.com — evidence-based medicine for everyday people. Fewer bad days. More good decades.
References
1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2026. Diabetes Care. American Diabetes Association. 2026;49(Supplement_1):S13. https://doi.org/10.2337/dc26-S001
2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026. https://doi.org/10.1161/CIR.0000000000001423
3. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. JAMA. 2022;328(8):746–753. doi:10.1001/jama.2022.13044
4. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for CVD Prevention in Adults. JAMA. 2020;324(20):2069. doi:10.1001/jama.2020.21749
5. Starr RR. Too Little, Too Late: Ineffective Regulation of Dietary Supplements in the United States. Am J Public Health. 2015;105(3):478–485. doi:10.2105/AJPH.2014.302348
